BioSpace News Archive

Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, up to $50.0 million of shares of its common stock in an underwritten public offering.

Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSX VENTURE:ASG) announced the appointment of Jana F. Kiena as their Chief Financial Officer (CFO), effective December 17, 2019.

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that positive results from the ongoing TransCarotid Artery Revascularization (TCAR) Surveillance Project comparing TCAR and transfemoral carotid artery stenting (TF-CAS) have been published in The Journal of the American Medical Association (JAMA)1.

Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced that its Board of Directors has approved a stock repurchase program, authorizing the repurchase of up to $50 million of the Company’s common stock.

Endo International plc announced that members of management will present at the J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 13, 2020 at 3:30 p.m. PST.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that Eldon Mayer has resigned from his position as chief commercial officer effective December 23, 2019, to pursue an opportunity with an emerging company.

ADVANZ PHARMA Corp. (“ADVANZ PHARMA” or “the Company”) (TSX: ADVZ), a global pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with enhanced access to high quality, niche-established medicines, today announced that shareholders voted 97.3 per cent in favour of a special resolution approving the continuance of the Company from Canada to Jersey, Channel Islands.

Strategic Transaction Benefits and Improves Aquaculture Health and Performance

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) voted 9-4 in favor of recommending KEYTRUDA, Merck’s anti-PD-1 therapy, for the treatment of certain patients with high-risk, non-muscle invasive bladder cancer (NMIBC).

Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the completion of the Shortened AGGRASTAT® (tirofiban hydrochloride) injection versus Integrilin® (eptifibatide) in Percutaneous Coronary Intervention (SAVI-PCI) Clinical Trial.